Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NTLA 
Intellia Therapeutics Inc (NTLA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NTLA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $34.57
1 Year Target Price $34.57
| 18 | Strong Buy |
| 4 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.62% | Avg. Invested days 16 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.67B USD | Price to earnings Ratio - | 1Y Target Price 34.57 |
Price to earnings Ratio - | 1Y Target Price 34.57 | ||
Volume (30-day avg) 29 | Beta 2.38 | 52 Weeks Range 5.90 - 26.98 | Updated Date 10/17/2025 |
52 Weeks Range 5.90 - 26.98 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.69 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -772.17% |
Management Effectiveness
Return on Assets (TTM) -30.62% | Return on Equity (TTM) -56.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1837110349 | Price to Sales(TTM) 50.59 |
Enterprise Value 1837110349 | Price to Sales(TTM) 50.59 | ||
Enterprise Value to Revenue 34.76 | Enterprise Value to EBITDA -5.51 | Shares Outstanding 107346886 | Shares Floating 101924795 |
Shares Outstanding 107346886 | Shares Floating 101924795 | ||
Percent Insiders 4.89 | Percent Institutions 88.02 |
Upturn AI SWOT
Intellia Therapeutics Inc
Company Overview
History and Background
Intellia Therapeutics Inc. was founded in 2014, based on the CRISPR/Cas9 gene editing technology. A significant milestone was the demonstration of in vivo gene editing in humans. The company has evolved into a leader in CRISPR-based therapies.
Core Business Areas
- In Vivo Gene Editing: Development of therapies that edit genes directly inside the patient's body. This is Intellia's primary focus.
- Ex Vivo Cell Therapies: Engineering cells outside the body and then transplanting them back into the patient. Focuses on immuno-oncology and autoimmune diseases.
Leadership and Structure
Intellia is led by a management team including the CEO and various VPs responsible for R&D, clinical development, and business operations. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- NTLA-2001: An in vivo CRISPR therapy targeting transthyretin (TTR) amyloidosis. Early clinical data shows promising results. Competitors include Alnylam Pharmaceuticals (ALNY) with RNAi therapies and Ionis Pharmaceuticals (IONS) with antisense oligonucleotides. Market share data is premature as the product is still in clinical trials. But estimated to be $3B total sales per year once product is approved.
- NTLA-2002: An in vivo CRISPR therapy for hereditary angioedema (HAE). Currently in clinical trials. Competitors include BioCryst Pharmaceuticals (BCRX) and Takeda Pharmaceutical Company (TAK). Market share data is premature as the product is still in clinical trials. But estimated to be $2B total sales per year once product is approved.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR technology and the potential to treat genetic diseases. Intense competition and regulatory scrutiny are key factors.
Positioning
Intellia is a leading player in the CRISPR gene editing field, particularly focused on in vivo applications. Their competitive advantage lies in their proprietary technology and early clinical data.
Total Addressable Market (TAM)
The TAM for gene editing therapies is estimated to reach tens of billions of dollars. Intellia is positioned to capture a significant share of this market with its pipeline of in vivo therapies. Estimated around $25B.
Upturn SWOT Analysis
Strengths
- Leading CRISPR technology
- Strong intellectual property portfolio
- Promising early clinical data
- Experienced management team
- Strategic partnerships with Regeneron
Weaknesses
- High R&D costs
- Regulatory uncertainty
- Clinical trial risks
- Reliance on CRISPR technology (potential for alternative technologies to emerge)
Opportunities
- Expanding pipeline of therapies
- Strategic partnerships and collaborations
- Addressing unmet medical needs
- Advancements in CRISPR technology
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Regulatory hurdles
- Ethical concerns surrounding gene editing
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Intellia competes with other gene editing companies based on technology, clinical trial results, and intellectual property. Intellia's in vivo focus differentiates it to some extent.
Growth Trajectory and Initiatives
Historical Growth: Intellia has experienced significant growth in research and development activities, reflected in increased spending and pipeline expansion.
Future Projections: Analysts project continued revenue growth driven by clinical trial progress and potential product launches. Growth highly dependent on successful trials.
Recent Initiatives: Recent initiatives include expansion of clinical trials for NTLA-2001 and NTLA-2002, and strategic partnerships with Regeneron.
Summary
Intellia Therapeutics is a promising biotech company at the forefront of CRISPR gene editing. The company's focus on in vivo therapies and early clinical success are encouraging signs. Intellia's high R&D costs and regulatory uncertainties pose challenges that must be addressed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data may be outdated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intellia Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2016-05-06 | President, CEO & Director Dr. John M. Leonard M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 403 | Website https://www.intelliatx.com |
Full time employees 403 | Website https://www.intelliatx.com | ||
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.